Fig. 4.

CDR net charge is inversely correlated with the specificity of clinical-stage mAbs. (A) Logistic regression analysis of the specificity of 137 clinical-stage mAbs (approved antibody drugs or antibodies in clinical trials) as a function of CDR net charge at pH 7.4. Non-specific binding was evaluated using a panel of six biomolecules (cardiolipin, keyhole limpet hemocyanin, lipopolysaccharide, single stranded DNA, double stranded DNA and insulin). Clinical-stage mAbs were flagged if their ELISA non-specific binding signals exceed a value of 1.9 signal/background (Jain et al., 2017). The mAbs were binned based on their CDR net charge values, and the number of antibodies in each bin is reported above each bar. (B) Receiver operating characteristic curve analysis. The corresponding area under curve (AUC) value is also reported.